Romiplostim treatment of chemotherapy-induced thrombocytopenia Journal Article
| Authors: | Soff, G. A.; Miao, Y.; Bendheim, G.; Batista, J.; Mones, J. V.; Parameswaran, R.; Wilkins, C. R.; Devlin, S. M.; Abou-Alfa, G. K.; Cercek, A.; Kemeny, N. E.; Sarasohn, D. M.; Mantha, S. |
| Article Title: | Romiplostim treatment of chemotherapy-induced thrombocytopenia |
| Abstract: | PURPOSE: Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS: We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid tumors with CIT. Before enrollment, patients had platelets less than 100,000/μL for at least 4 weeks, despite delay or dose reduction of chemotherapy. Patients received weekly titrated romiplostim with a target platelet count of 100,000/μL or more, or were monitored with usual care. The primary end point was correction of platelet count within 3 weeks. Twenty-three patients were treated in a randomization phase, and an additional 37 patients were treated in a single-arm, romiplostim phase. Resumption of chemotherapy without recurrent CIT was a secondary end point. RESULTS: The mean platelet count at enrollment was 62,000/μL. In the randomization phase, 14 of 15 romiplostim-treated patients (93%) experienced correction of their platelet count within 3 weeks, compared with one of eight control patients (12.5%; P < .001). Including all romiplostim-treated patients (N = 52), the mean platelet count at 2 weeks of treatment was 141,000/μL. The mean platelet count in the eight observation patients at 3 weeks was 57,000/μL. Forty-four patients who achieved platelet correction with romiplostim resumed chemotherapy with weekly romiplostim. Only three patients (6.8%) experienced recurrent reduction or delay of chemotherapy because of isolated CIT. CONCLUSION: This prospective trial evaluated treatment of CIT with romiplostim. Romiplostim is effective in correcting CIT, and maintenance allows for resumption of chemotherapy without recurrence of CIT in most patients. |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 31 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-11-01 |
| Start Page: | 2892 |
| End Page: | 2898 |
| Language: | English |
| DOI: | 10.1200/jco.18.01931 |
| PUBMED: | 31545663 |
| PROVIDER: | scopus |
| PMCID: | PMC6823892 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work